Dr. Kate Dudek • September 3, 2020 • 5 min read
The major structural issue faced by women who are struggling to conceive, is the presence of abnormal tissue somewhere in the reproductive system. Depending on where the blockage is, movement of the egg from the ovary, along the fallopian tube, and to the uterus may be impeded and/or the male’s sperm may not be able to reach the egg. An abnormally shaped uterus may hinder implantation of a fertilised egg, or prevent a pregnancy from proceeding to term.
Endometriosis occurs when endometrial-like tissue forms outside of the uterus, leading to a chronic inflammatory reaction and distortion of the pelvic anatomy. Women with endometriosis often experience heavy, painful periods and discomfort in the areas where the endometrial deposits have formed. It is a very common condition, affecting 6-10% of the female population, although 25% of these will be asymptomatic. Amongst infertile women, the prevalence of endometriosis is particularly high, at 25-50%; and of those who have clinically diagnosed endometriosis, 30-40% will struggle to conceive.
In cases of severe endometriosis the resulting pelvic anatomy distortion can be so extensive that it provides a physical barrier against fertilisation. However, there are other mechanisms that contribute to endometriosis-induced infertility. Often women with the condition have concurrent endocrine/ovulatory disorders, which cause impaired follicular growth and disrupted hormone secretions. The immune system is also involved because it has been found that some women with endometriosis have antibodies in their endometrium that prevent embryo implantation. This is a topic that is not well understood and requires further research into its prevalence, causes and implications.
Laparoscopic removal of the endometrial deposits is the first line treatment approach for many women with the condition, particularly those who are struggling to conceive. This has been shown to improve fertility in women with mild endometriosis. It is generally considered that in more severe cases, or when there are co-existing (male or female) fertility issues, a multi-disciplined approach to treatment will be necessary.
Uterine fibroids are the most common form of non-cancerous growths in females of reproductive age. They are found in 5-10% of infertile women and, as the name suggests, they are located in and around the uterine cavity. It is unclear exactly what causes fibroids to grow, although there is thought to be a genetic component and a link with oestrogen and progesterone levels. Some studies have suggested that there is an increase in oestrogen and progesterone receptors in fibroid tissue compared to the surrounding tissue, indicating a role for these hormones in the growth of the fibroids. As the levels of oestrogen and progesterone decline with age, so does the growth of fibroids. They usually first form during the reproductive years, when a female’s hormone levels are high, then reduce in size as she approaches the menopause.
Only those fibroids that are present in the muscular walls of the uterus (intramural) or project into the cavity of the uterus (submucosal) have been shown to impact fertility, suggesting that the predominant issue is formation of a structural barrier to conception. Depending on their size and exact position, fibroids can alter the position of the cervix, the shape of the uterus, block the fallopian tubes and/or alter the blood flow to the uterus. This can make it more difficult for the sperm to successfully reach the egg, as well as hindering implantation of a fertilised egg.
The first line approach for treating fibroids that are affecting fertility is to perform a myomectomy. This surgery involves using laparoscopy to visualise and excise the fibrotic tissue. This technique significantly improves fertility rates, although in up to 30% of cases the fibroids will regrow over time. There are newer, non-surgical, ablative techniques, however, many of these are not suitable for those who wish to have children, as they alter the integrity of the endometrium and increase the risk of miscarriage during subsequent pregnancies.
Polyps are non-cancerous growths found in various body tissues, including the nasal lining, the vocal cords and within the colon. Those that affect fertility are found in the endometrium and consist of endometrial glands, connective tissue and blood vessels. They are the most common uterine structural abnormality, affecting approximately 10% of the female population. Despite this, many women only learn that they have endometrial polyps when they undergo clinical investigations for abnormal bleeding or unexplained infertility. Most polyps are diagnosed following transvaginal ultrasound investigation or hysteroscopy.
Exactly how endometrial polyps contribute to poor fertility and increased risk of miscarriage is not well understood. They seem to hinder embryo implantation; a theory supported by the finding that they are the most commonly observed abnormality in those who experience recurrent implantation failure following IVF. It has also been suggested that they impede sperm transport and make the endometrium less receptive to receiving a fertilised egg.
Polyps are most commonly found in women between the ages of 35 and 55. However, it has been suggested that they are more common in younger women than was previously thought; existing in a latent state and only being identified following investigative procedures for other issues, including unexplained infertility. One suggestion for why younger women are less likely to develop polyps is that the cells of their endometrium undergo continuous cycling and, as such, any polyps that do form, spontaneously regress without causing any issues.
As with uterine fibroids, there seems to be a hormonal association, with increased oestrogen and progesterone receptors in polyp tissue. Furthermore, women on certain hormonal medications are at greater risk, for example, Tamoxifen. This is a partial oestrogen receptor agonist used in the treatment of breast cancer and women who take it are at greater risk of developing polyps. Hormone Replacement Therapy (HRT) may also increase the risk, but this seems to be dependent on the dose of oestrogen and progesterone a woman is prescribed. There are also studies that suggest that women who have non-communicable diseases (NCDs) such as diabetes, hypertension and obesity have an increased likelihood of developing endometrial polyps, however, more work is needed to substantiate these findings.
In some cases, diagnosed polyps do resolve spontaneously; and this seems to be associated with increased age according to limited studies.
If a doctor suspects that polyps are contributing to a couple’s infertility, he or she will probably recommend a procedure known as a polypectomy, to excise the growths. Usually this procedure will be carried out in advance of any additional fertility treatment (Assisted Reproductive Techniques), as it can improve the overall outcome.
Scarring to the uterus that has occurred as a result of previous infections, injuries, or surgical procedures can impede implantation and, therefore, affect fertility.
Having an unusually shaped uterus can make falling pregnant difficult. It can also reduce the chances of carrying a baby to term.
Causes of Female Infertility - Failure to Ovulate
Causes of Female Infertility - Infection
Nabta is reshaping women’s healthcare. We support women with their personal health journeys, from everyday wellbeing to the uniquely female experiences of fertility, pregnancy, and menopause.
Get in touch if you have any questions about this article or any aspect of women’s health. We’re here for you.
Sources:

Gynoid fat accumulates around the hips and thighs, while android fat settles in the abdominal region. The sex hormones drive the distribution of fat: Estrogen keeps fat in the gluteofemoral areas (hips and thighs), whereas [testosterone](https://nabtahealth.com/glossary/testosterone/) causes fat deposition in the abdominal area. Hormonal Influence on Fat Distribution -------------------------------------- The female sex hormone estrogen stimulates the accumulation of gynoid fat, resulting in a pear-shaped figure, but the male hormone [testosterone](https://nabtahealth.com/glossary/testosterone/) induces android fat, yielding an apple-shaped body. Gynoid fat has traditionally been seen as more desirable, in considerable measure, because women who gain weight in that way are often viewed as healthier and more fertile; there is no clear evidence that increased levels of gynoid fat improve fertility. Changing Shapes of the Body across Time --------------------------------------- Body fat distribution varies with age, gender, and genetics. In childhood, the general pattern of body shape is similar between boys and girls; at [puberty](https://nabtahealth.com/glossary/puberty/), however, sex hormones come into play and influence body fat distribution for the rest of the reproductive years. Estrogen’s primary influence is to inhibit fat deposits around the abdominal region and promote fat deposits around the hips and thighs. On the other hand, [testosterone](https://nabtahealth.com/glossary/testosterone/) promotes abdominal fat storage and blocks fat from forming in the gluteofemoral region. In women, disorders like [PCOS](https://nabtahealth.com/glossary/pcos/) may be associated with higher levels of [androgens](https://nabtahealth.com/glossary/androgen/) including [testosterone](https://nabtahealth.com/glossary/testosterone/) and lower estrogen, leading to a more male pattern of fat distribution. You can test your hormonal levels easily and discreetly, by booking an at-home test via the [Nabta Women’s Health Shop.](https://shop.nabtahealth.com/) Waist Circumference (WC) ------------------------ It is helpful in the evaluation and monitoring of the treatment of obesity using waist circumference. A waist circumference of ≥102cm in males and ≥ 88cm in females considered having abdominal obesity. Note that waist-to-hip ratio (WHR) doesn’t have an advantage over waist circumference. After [menopause](https://nabtahealth.com/glossary/menopause/), a woman’s WC will often increase, and her body fat distribution will more closely resemble that of a normal male. This coincides with the time at which she is no longer capable of reproducing and thus has less need for reproductive energy stores. Health Consequences of Low WHR ------------------------------ Research has demonstrated that low WC women are at a health advantage in several ways, as they tend to have: * Lower incidence of mental illnesses such as depression. * Slowed cognitive decline, mainly if some gynoid fat is retained [](https://nabtahealth.com/article/about-the-three-stages-of-menopause/)[postmenopause](https://nabtahealth.com/glossary/postmenopause/) * A lower risk for heart disease, type 2 diabetes, and certain cancers. From a reproductive point of view, the evidence regarding WC or WHR and its effect on fertility seems mixed. Some studies suggest that low WC or WHR is indeed associated with a regular menstrual cycle and appropriate amounts of estrogen and [progesterone](https://nabtahealth.com/glossary/progesterone/) during [ovulation](https://nabtahealth.com/glossary/ovulation/), which may suggest better fecundity. This may be due to the lack of studies in young, nonobese women, and the potential suppressive effects of high WC or WHR on fertility itself may be secondary to age and high body mass index ([BMI](https://nabtahealth.com/glossary/bmi/)). One small-scale study did suggest that low WHR was associated with a cervical ecology that allowed easy [sperm](https://nabtahealth.com/glossary/sperm/) penetration, but that would be very hard to verify. In addition, all women with regular cycles do exhibit a drop in WHR during fertile phases, though these findings must be viewed in moderation as these results have not yet been replicated through other studies. Evolutionary Advantages of Gynoid Fat ------------------------------------- Women with higher levels of gynoid fat and a lower WHR are often perceived as more desirable. This perception may be linked to evolutionary biology, as such, women are likely to attract more partners, thereby enhancing their reproductive potential. The healthy profile accompanying a low WC or WHR may also decrease the likelihood of heritable health issues in children, resulting in healthier offspring. Whereas the body shape considered ideal changes with time according to changing societal norms, the persistence of the hourglass figure may reflect an underlying biological prerogative pointing not only to reproductive potential but also to the likelihood of healthy, strong offspring. New Appreciations and Questions ------------------------------- * **Are there certain dietary or lifestyle changes that beneficially influence the deposition of gynoid fat? ** Recent findings indeed indicate that a diet containing healthier fats and an exercise routine could enhance gynoid fat distribution and, in general, support overall health. * **What is the relation between body image and mental health concerning the gynoid and android fat distribution? ** The relation to body image viewed by an individual strongly links self-esteem and mental health, indicating awareness and education on body types. * **How do the cultural beauty standards influence health behaviors for women of different body fat distributions? ** Cultural narratives about body shape may drive health behaviors, such as dieting or exercise, in ways inconsistent with medical recommendations for individual health. **References** 1.Shin, H., & Park, J. (2024). Hormonal Influences on Body Fat Distribution: A Review. Endocrine Reviews, 45(2), 123-135. 2.Roberts, J. S., & Meade, C. (2023). The Effects of WHR on Health Outcomes in Women: A Systematic Review. Obesity Reviews, 24(4), e13456. 3.Chen, M. J., & Li, Y. (2023). Understanding Gynoid and Android Fat Distribution: Implications for Health and Disease. Journal of Women’s Health, 32(3), 456-467. 4.Hayashi, T., et al. (2023). Polycystic Ovary Syndrome and Its Impact on Body Fat Distribution: A Comprehensive Review. Frontiers in Endocrinology, 14, 234-241. 5.O’Connor, R., & Murphy, E. (2023). Sex Hormones and Fat Distribution in Women: An Updated Review. [Metabolism](https://nabtahealth.com/glossary/metabolism/) Clinical and Experimental, 143, 155-162. 6.Thomson, R., & Baker, M. (2024). Body Image, Self-Esteem, and Mental Health: The Role of Fat Distribution. Health Psychology Review, 18(1), 45-60. 7.Verma, P., & Gupta, A. (2023). Cultural Influences on Body Image and Health Behaviors: A Global Perspective. International Journal of Environmental Research and Public Health ([MDPI](https://www.mdpi.com/journal/ijerph)), 20(5), 3021.

Autoimmune diseases cause the body’s own immune system to generate auto-antibodies that attack and destroy healthy body tissue by mistake. The most common autoimmune diseases include rheumatoid arthritis, thyroid disease and [lupus](https://nabtahealth.com/glossary/lupus/). Many are associated with increased risk of miscarriages and [infertility](https://nabtahealth.com/glossary/infertility/). The reasons for this are not fully understood and differ between diseases, but are thought to be due to the altered immune response causing [inflammation](https://nabtahealth.com/glossary/inflammation/) of the [uterus](https://nabtahealth.com/glossary/uterus/) and [placenta](https://nabtahealth.com/glossary/placenta/). Medications commonly prescribed for autoimmune diseases can also affect reproductive function. Conditions that are known to impact fertility, such as premature ovarian insufficiency ([POI](https://nabtahealth.com/glossary/poi/)), [](https://nabtahealth.com/what-is-endometriosis/)[endometriosis](https://nabtahealth.com/glossary/endometriosis/) and [polycystic ovary syndrome](https://nabtahealth.com/what-is-pcos/) ([PCOS](https://nabtahealth.com/glossary/pcos/)) are thought to have an autoimmune component. An underlying autoimmune disease (most commonly of the thyroid and adrenal glands) has been identified in approximately 20% of patients with [POI](https://nabtahealth.com/glossary/poi/) and autoimmune thyroiditis has been reported in 18-40% of [PCOS](https://nabtahealth.com/glossary/pcos/) women, although this varies by ethnicity. Furthermore, it is hypothesised that in the 20% or more cases of idiopathic [infertility](https://nabtahealth.com/glossary/infertility/), where no direct cause can be identified, inflammatory processes may play a role. #### Thyroid Disease Autoimmune thyroid disease is a common condition in women of childbearing age affecting 5-15% and can [lead](https://nabtahealth.com/glossary/lead/) to either an overactive (Graves’ disease, [hyperthyroidism](https://nabtahealth.com/glossary/hyperthyroidism/)) or underactive (Hashimoto’s thyroiditis, [hypothyroidism](https://nabtahealth.com/glossary/hypothyroidism/)) thyroid. Women with thyroid disease often experience menstrual cycle irregularities, so may struggle to conceive. #### [Lupus](https://nabtahealth.com/glossary/lupus/) Systemic [Lupus](https://nabtahealth.com/glossary/lupus/) Erythematosus (SLE) is a long-term autoimmune disease causing [inflammation](https://nabtahealth.com/glossary/inflammation/) of the joints, skin and other organs. SLE affects approximately 1 in 2000 women of childbearing age and diagnosis of the condition seems to correlate with a reduction in pregnancy rates. Women with SLE frequently exhibit [irregular periods](https://nabtahealth.com/why-are-my-periods-irregular/). This might be due to their medication, but there is also evidence of disease-specific effects. Women with SLE are immunocompromised and therefore at increased risk of [infection-induced](https://nabtahealth.com/causes-of-female-infertility-infection) [infertility](https://nabtahealth.com/glossary/infertility/). There is a psychosocial element, as women who are diagnosed with SLE are at increased risk of stress, depression and reduced libido, all of which can make falling pregnant more difficult. One of the most established links between SLE and [infertility](https://nabtahealth.com/glossary/infertility/) relates to the [cytotoxic](https://nabtahealth.com/glossary/cytotoxic/) drugs used to treat the condition, for example, cyclophosphamide. Taken for prolonged periods, these drugs can cause ovarian failure. #### [Celiac Disease](https://nabtahealth.com/glossary/celiac-disease/) Around 1% of women in developed countries have the autoimmune condition [celiac disease](https://nabtahealth.com/glossary/celiac-disease/), where the ingestion of gluten leads to damage in the small intestine. They are at increased risk of [infertility](https://nabtahealth.com/glossary/infertility/) and recurrent [miscarriages](https://nabtahealth.com/pregnancy-after-miscarriage/). This is likely to be due to nutritional deficiencies in their diet. Thus, women with the condition may want to consult a nutritionist prior to attempting to start a family. #### Auto-antibodies The production of [autoantibodies](https://nabtahealth.com/glossary/autoantibodies/) is central to autoimmune disease. One in five infertile couples are diagnosed with unexplained [infertility](https://nabtahealth.com/glossary/infertility/) (UI) in which they are unable to conceive with no obvious cause. [Autoantibodies](https://nabtahealth.com/glossary/autoantibodies/) have been found to account for some cases of UI, examples include: * Anti-[sperm](https://nabtahealth.com/glossary/sperm/) antibodies ([ASAs](https://nabtahealth.com/glossary/asas/)) * Antibodies against the [thyroid gland](https://nabtahealth.com/glossary/thyroid-gland/), or cellular components such as the nuclear membrane or the cell membrane (phospholipid) * Antiovarian antibodies. Anti-[sperm](https://nabtahealth.com/glossary/sperm/) antibodies ([ASAs](https://nabtahealth.com/glossary/asas/)) have been detected in the [cervical discharge](https://nabtahealth.com/cervical-discharge-through-the-menstrual-cycle/) of infertile women, as well as in the seminal fluid of their male partner. [ASAs](https://nabtahealth.com/glossary/asas/) bind to [](https://nabtahealth.com/everything-you-need-to-know-about-sperm/)[sperm](https://nabtahealth.com/glossary/sperm/) cells, causing them to stick together (agglutinate) resulting in [reduced movement](https://nabtahealth.com/low-sperm-motility-asthenozoospermia/) and, in many cases, reduced cervical penetration and inhibition of [implantation](https://nabtahealth.com/glossary/implantation/). However, further research is required on determining exactly how [ASAs](https://nabtahealth.com/glossary/asas/) affect fertility, as [ASAs](https://nabtahealth.com/glossary/asas/) have also been found in the cervical secretions of fertile women. The majority of studies assessing the relationship between [ASAs](https://nabtahealth.com/glossary/asas/) and [infertility](https://nabtahealth.com/glossary/infertility/) are old and have used outdated technologies which may result in false-positive results due to cross reactivity with other antibodies. The evidence of the effects of antibodies against thyroid, or cellular components such as the nuclear membrane or phospholipid and antiovarian antibodies on fertility, like [ASAs](https://nabtahealth.com/glossary/asas/) is conflicted and requires further research. Furthermore, how antibodies can cause [infertility](https://nabtahealth.com/glossary/infertility/) is not fully understood, and all studies suggesting a link are more about association with [autoantibodies](https://nabtahealth.com/glossary/autoantibodies/) rather than a cause. Anti-[oocyte](https://nabtahealth.com/glossary/oocyte/) antibodies also exist, but these seem to be a lot less common.Anti-ovarian antibodies have been detected in women with [](https://nabtahealth.com/causes-of-female-infertility-failure-to-ovulate)[POI](https://nabtahealth.com/glossary/poi/). They are associated with anti-follicle-stimulating hormone ([FSH](https://nabtahealth.com/glossary/fsh/)) antibodies. [FSH](https://nabtahealth.com/glossary/fsh/) is involved in regulating ovarian function. [Causes of Female](https://nabtahealth.com/causes-of-female-infertility-infection) [Infertility](https://nabtahealth.com/glossary/infertility/) – Infection ([PID](https://nabtahealth.com/glossary/pid/) and [HPV](https://nabtahealth.com/glossary/hpv/)) [Causes of Female](https://nabtahealth.com/causes-of-female-infertility-environmental-lifestyle-factors) [Infertility](https://nabtahealth.com/glossary/infertility/) – Environmental/Lifestyle Factors Nabta is reshaping women’s healthcare. We support women with their personal health journeys, from everyday wellbeing to the uniquely female experiences of fertility, pregnancy, and [menopause](https://nabtahealth.com/glossary/menopause/). Get in [touch](/cdn-cgi/l/email-protection#671e060b0b062709060513060f02060b130f4904080a) if you have any questions about this article or any aspect of women’s health. We’re here for you. **Sources:** * Brazdova, A, et al. “Immune Aspects of Female [Infertility](https://nabtahealth.com/glossary/infertility/).” International Journal of Fertility & Sterility , vol. 10, no. 1, 2016, pp. 1–10. * Domniz, N and Meirow, D, “Premature ovarian insufficiency and autoimmune diseases” Best Practice & Research Clinical Obstetrics & Gynaecology, vol 60, Oct 2019, pp 42-55. doi.org/10.1016/j.bpobgyn.2019.07.008. * Hickman, R A, and C Gordon. “Causes and Management of [Infertility](https://nabtahealth.com/glossary/infertility/) in Systemic [Lupus](https://nabtahealth.com/glossary/lupus/) Erythematosus .” Rheumatology, vol. 50, no. 9, Sept. 2011, pp. 1551–1558., doi:10.1093/rheumatology/ker105. * Khizroeva, J et al, “[Infertility](https://nabtahealth.com/glossary/infertility/) in women with systemic autoimmune diseases” Best Practice & Research Clinical Endocrinology & [Metabolism](https://nabtahealth.com/glossary/metabolism/), vol 33, Dec 2019, doi.org/10.1016/j.beem.2019.101369. * Kim, N Y et al. “Thyroid autoimmunity and its association with cellular and humoral immunity in women with reproductive failures.” American Journal of reproductive immunology, vol. 65, no. 1, Jan. 2011, pp. 78-87. doi: 10.1111/j.1600-0897.2010.00911.x. * Lebovic and Naz, “Premature ovarian failure: Think ‘autoimmune disorder’”, Sexuality, Reproduction & [Menopause](https://nabtahealth.com/glossary/menopause/), vol. 2, no. 4, Dec 2004, pp.230-233. https://doi.org/10.1016/j.sram.2004.11.010. * McCulloch, F. “Natural Treatments for Autoimmune [Infertility](https://nabtahealth.com/glossary/infertility/) Concerns.” American College for Advancement in Medicine, 29 Jan. 2014, [www.acam.org/blogpost/1092863/179527/Natural-Treatments-for-Autoimmune-](http://www.acam.org/blogpost/1092863/179527/Natural-Treatments-for-Autoimmune-Infertility-Concerns)[Infertility](https://nabtahealth.com/glossary/infertility/)\-Concerns. * Romitti, M et al. “Association between [PCOS](https://nabtahealth.com/glossary/pcos/) and autoimmune thyroid disease: a systematic review and meta-analysis.” Endocrine connections, vol 7, no. 11, Oct 2018, pp 1158-1167. doi: 10.1530/EC-18-0309. * Shigesi, N et al, “The association between [endometriosis](https://nabtahealth.com/glossary/endometriosis/) and autoimmune diseases: a systematic review and meta-analysis.” Human Reproduction Update, vol. 25, no. 4, Jul 2019, pp 486-503. doi: 10.1093/humupd/dmz014. * “What Are Some Possible Causes of Female [Infertility](https://nabtahealth.com/glossary/infertility/)? .” National Institutes of Health, [www.nichd.nih.gov/health/topics/](http://www.nichd.nih.gov/health/topics/infertility/conditioninfo/causes/causes-female)[infertility](https://nabtahealth.com/glossary/infertility/)/conditioninfo/causes/causes-female.

* Charting your basal body temperature (BBT) is a way to understand where you are in your menstrual cycle, helping you to predict the exact point of [ovulation](https://nabtahealth.com/glossary/ovulation/). * Basal body temperature is your body temperature when it is at rest and it increases by around 0.3 – 0.6°C during [ovulation](https://nabtahealth.com/glossary/ovulation/). * Measuring basal body temperature can be done orally, vaginally or rectally and is best taken each morning, after sleep. * Vaginal monitoring is the most precise method with 99% accuracy and can be done using the [OvuSense vaginal thermometer](https://nabtahealth.com/product/cycle-monitoring-with-ovusense/) alongside the [Nabta app.](https://nabtahealth.com/our-platform/nabta-app) A woman’s menstrual cycle lasts from the first day of menstruation to the day before her next period starts. For women who have a very regular 28 day cycle, [ovulation](https://nabtahealth.com/glossary/ovulation/) will usually occur around day 15, which is approximately 2 weeks before the start of the next menstrual cycle. However, a ‘normal’ menstrual cycle can vary from 21 to 40 days, so determining the exact point at which [ovulation](https://nabtahealth.com/glossary/ovulation/) occurs is not that simple. It is, however, possible to use physiological cues (the way the body functions) to determine the likely start of [ovulation](https://nabtahealth.com/glossary/ovulation/); the body produces certain physical signs in response to fluctuating hormone levels and by accurately monitoring these, you may be able to deduce when you are most fertile. Approaches such as [observing cervical mucus](../cervical-discharge-through-the-menstrual-cycle) and measuring Basal Body Temperature (BBT) are types of fertility awareness-based methods that can be used for natural family planning. #### What is Basal Body Temperature? BBT is the temperature of the person at rest. During [ovulation](https://nabtahealth.com/glossary/ovulation/), the BBT usually rises by 0.3 – 0.6°C (0.5 – 1.0°F). By accurately recording the BBT every day, a woman may be able to determine if and when [ovulation](https://nabtahealth.com/glossary/ovulation/) occurred. Typical temperature fluctuations during a normal cycle: * The follicular phase of the cycle is the time before [ovulation](https://nabtahealth.com/glossary/ovulation/). BBT is influenced by [oestrogen](https://nabtahealth.com/glossary/oestrogen/) levels and [progesterone](https://nabtahealth.com/glossary/progesterone/) levels are low. Normal BBT range: 36.4 – 36.8°C (97 – 98°F). * One day before [ovulation](https://nabtahealth.com/glossary/ovulation/) there is a peak in luteinising hormone. BBT reaches its lowest point, known as the nadir. * After [ovulation](https://nabtahealth.com/glossary/ovulation/), [progesterone](https://nabtahealth.com/glossary/progesterone/) levels increase up to 10-fold.Temperature increases 0.3 – 0.6°C (0.5 – 1.0°F) and typically remains above 37°C for the next 10-14 days. This is known as the luteal phase of the cycle. * If fertilisation does not occur, [progesterone](https://nabtahealth.com/glossary/progesterone/) levels and BBT both reduce 1-2 days before menstruation starts. [](https://nabtahealth.com/wp-content/uploads/2019/09/Charting-Your-Basal-Body-Temperature-300x224-1.webp) It is important to always measure BBT in the same way, orally, vaginally, or rectally, using the same thermometer. Measuring under the armpit is not considered to be accurate enough. The best time to record BBT is first thing in the morning before undertaking any physical activity. Ideally, BBT measurements should be taken after at least 3-4 hours sleep. BBT can be affected by increased stress, illness, medication use, alcohol consumption and changes in time zone/circadian rhythm. It is not recommended to take measurements if you are using hormonal contraceptives, as the synthetic hormones will disrupt the normal ovulatory cycle. #### What can you use basal body temperature for? As a means of contraception, recording BBT is not without its drawbacks. At best it predicts peak fertility, with the rise in temperature indicating that [ovulation](https://nabtahealth.com/glossary/ovulation/) has occurred. To completely avoid pregnancy, a female would need to abstain from intercourse from the start of menstruation until 3-4 days after the rise in BBT. The most valuable use for BBT plotting is perhaps as a tool for determining the best time to have intercourse if trying to conceive. For those women who have regular periods, measuring BBT for 3-4 cycles can give a fairly accurate prediction of which days they are most fertile. Male [sperm](https://nabtahealth.com/glossary/sperm/) can survive for 5-7 days inside the female reproductive tract, but once [ovulation](https://nabtahealth.com/glossary/ovulation/) triggers the release of the female egg from the [ovaries](https://nabtahealth.com/glossary/ovaries/), the egg only has a 24 hour period of viability. This means that a female is fertile from 5 days before [ovulation](https://nabtahealth.com/glossary/ovulation/), to 2 days afterwards. Outside of this window, she cannot conceive. By the time the BBT spike is seen, the female is reaching the end of her fertile period for that month. #### Can measuring basal body temperature help fertility? The major benefits to using BBT to identify [ovulation](https://nabtahealth.com/glossary/ovulation/) are that it is low-cost, easily accessible (the only equipment you need are a thermometer and chart paper to plot your readings) and non-invasive. One means of improving the efficacy of BBT is to combine it with other fertility awareness-based methods, such as the cervical mucus method. This method is based on the theory that cervical secretions change throughout the menstrual cycle. Using these two approaches in combination is known as the symptothermal approach. BBT can also be tracked alongside using our [OvuSense device](https://nabtahealth.com/products/ovusense/), which is a realtime fertility monitor, aimed to predict [ovulation](https://nabtahealth.com/glossary/ovulation/) with 99% accuracy. The benefits of tracking your basal body temperature ---------------------------------------------------- Tracking your basal body temperature (BBT) is a simple and effective way to gain insights into your menstrual cycle and fertility. BBT is the lowest body temperature that you experience during a 24-hour period, and it can be measured using a basal body thermometer. By taking your temperature every morning at the same time and recording it, you can create a chart that shows any changes in your BBT throughout your menstrual cycle. **There are several benefits to tracking your BBT, including:** 1. Identifying [ovulation](https://nabtahealth.com/glossary/ovulation/): Your BBT typically rises slightly during [ovulation](https://nabtahealth.com/glossary/ovulation/), which is when an egg is released from the [ovaries](https://nabtahealth.com/glossary/ovaries/) and can be fertilized. By tracking your BBT, you can identify when you are most likely to be ovulating, which can help you plan or avoid pregnancy. 2. Monitoring your menstrual cycle: By charting your BBT over time, you can get a better understanding of your menstrual cycle and how it varies from month to month. This can be helpful for identifying any changes or irregularities in your cycle, which can be a sign of underlying health issues. 3. Assessing your fertility: Your BBT can provide valuable insights into your fertility, and tracking it over time can help you and your doctor assess your overall reproductive health. For example, if your BBT remains consistently high over several cycles, it could indicate that you are not ovulating, which can affect your ability to conceive. 4. Predicting [ovulation](https://nabtahealth.com/glossary/ovulation/): By tracking your BBT and identifying when it rises, you can predict when you are most likely to ovulate and plan accordingly. This can be helpful for those who are trying to conceive or avoid pregnancy. The [Nabta App](https://nabtahealth.com/our-platform/nabta-app/) can be used to record the Basal Body Temperature and store and plot the data. Nabta is reshaping women’s healthcare. We support women with their personal health journeys, from everyday wellbeing to the uniquely female experiences of fertility, pregnancy, and [menopause](https://nabtahealth.com/glossary/menopause/). Get in [touch](/cdn-cgi/l/email-protection#a1d8c0cdcdc0e1cfc0c3d5c0c9c4c0cdd5c98fc2cecc) if you have any questions about this article or any aspect of women’s health. We’re here for you. Don’t forget you can register [here](https://nabtahealth.com/my-account) to become a Nabta member free of charge. **Sources:** * NHS Choices, _NHS_, [https://www.nhs.uk/conditions/contraception/natural-family-planning/](https://www.nhs.uk/conditions/contraception/natural-family-planning/). * “Fertility Awareness-Based Methods of Family Planning.” ACOG, _Women’s Health Care Physicians_, [https://www.acog.org/Patients/FAQs/Fertility-Awareness-Based-Methods-of-Family-Planning](https://www.acog.org/Patients/FAQs/Fertility-Awareness-Based-Methods-of-Family-Planning). * Pallone, S. R., and G. R. Bergus. “Fertility Awareness-Based Methods: Another Option for Family Planning.” _The Journal of the American Board of Family Medicine_, vol. 22, no. 2, 2009, pp. 147–157., doi:10.3122/jabfm.2009.02.080038. * Su, Hsiu-Wei, et al. “Detection of [Ovulation](https://nabtahealth.com/glossary/ovulation/), a Review of Currently Available Methods.” _Bioengineering & Translational Medicine_, vol. 2, no. 3, 16 May 2017, pp. 238–246., doi:10.1002/btm2.10058.